...
首页> 外文期刊>Clinical and experimental metastasis >The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma
【24h】

The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma

机译:用透明细胞肾细胞癌的分子生物标志物测量药物的现状

获取原文
获取原文并翻译 | 示例
           

摘要

Appropriate use of multiple reliable molecular biomarkers in the right context will play a role in tailor-made medicine of clear cell renal cell carcinoma (RCC) patients in the future. A total of 11,056 patients from 53 studies were included in this review. The article numbers of the each evidence levels, using the grading system denned by the Oxford Centre for Evidence-based Medicine, in 1b, 2a, 2b, and 3b were 5 (9 %), 18 (34 %), 29 (55 %), and 1 (2 %), respectively. The main goal of using biomarkers is to refine predictions of tumor progression, pharmac otheraру responsiveness, and cancer-specific and/ or overall survival. Currently, carbonic anhydrase (CA9) and vascular endothelial growth factor (VEGF) inperipheral blood and p53 in tumor tissues are measured to predict metastasis, while VEGF-related proteins in peripheral blood are used to assess pharmacotherapy responsiveness with sunitinib. Furthermore, interleukin 8, osteopontin, hepatocyte growth factor, and tissue inhibitors of metalloproteinases-1 in peripheral blood enable assessment of responsiveness to pazopanib treatment. Other reliable molecular biomarkers include von Hippel-Lindau gene alteration, hypoxia-inducible factor-1alpha, CA9, and survivin in tumor tissues and VEGF in peripheral blood for predicting cancer-specific survival. In the future, studies should undergo external validation for developing tailored management of clear cell RCC with molecular biomarkers, since individual institutional studies lack the generalization and consistency required to maintain accuracy among different patient series.
机译:适当使用多种可靠的分子生物标志物在正确的背景下将在未来定制透明细胞肾细胞癌(RCC)患者的量身定制的药物作用。本次审查中共有来自53项研究的11,056名患者。每种证据水平的物品数量,使用由牛津医学的牛津医学置击,在1B,2A,2B和3B中的分级系统为5(9%),18(34%),29(55%)分别为1(2%)。使用生物标志物的主要目标是优化肿瘤进展,药物其他应对性和癌症特异性和/或整体存活的预测。目前,测量碳酸酐酶(CA9)和血管内皮生长因子(VEGF)肿瘤组织中的腔内血液和P53,以预测转移,而外周血中的VEGF相关蛋白质用于评估与Sunitinib的药物疗法反应性。此外,白细胞介素8,骨膨胀素,肝细胞生长因子和组织抑制剂在外周血中为1-1,可以评估对pazopanib治疗的反应性。其他可靠的分子生物标志物包括von Hippel-lindau基因改变,缺氧诱导因子-1Alpha,Ca9和肿瘤组织中的Survivin和外周血VEGF,用于预测癌症特异性存活。在未来,研究应接受外部验证,以便在分子生物标志物中制定透明细胞RCC的量身定制管理,因为个人制度研究缺乏在不同患者系列中保持准确性所需的泛化和一致性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号